



Document heading doi: 10.1016/S1995-7645(14)60314-X

## Antibiotic susceptibility profiling and virulence potential of *Campylobacter jejuni* isolates from different sources in Pakistan

Fariha Masood Siddiqui, Muhammad Akram, Nighat Noureen, Zobia Noreen, Habib Bokhari\*

Department of Biosciences, COMSATS Institute of Information Technology, Park Road, 44000, Islamabad, Pakistan

## ARTICLE INFO

## Article history:

Received 24 December 2014

Received in revised form 10 January 2015

Accepted 15 February 2015

Available online 20 March 2015

## Keywords:

*Campylobacter jejuni*

Antibiotic susceptibility

Virulence genes

PCR

RAPD

## ABSTRACT

**Objective:** To determine antibiotic resistance patterns and virulence potential of *Campylobacter jejuni* (*C. jejuni*) isolates from clinical human diarrheal infections, cattle and healthy broilers.

**Methods:** Antibiotic sensitivity patterns of *C. jejuni* isolates were determined by Kirby Bauer Disc Diffusion assay. These isolates were then subjected to virulence profiling for the detection of *mapA* (membrane-associated protein), *cadF* (fibronectin binding protein), *wlaN* (beta-1,3-galactosyltransferase) and *neuAB* (sialic acid biosynthesis gene). Further *C. jejuni* isolates were grouped by random amplification of polymorphic DNA (RAPD) profiling. **Results:** A total of 436 samples from poultry ( $n=88$ ), cattle ( $n=216$ ) and humans ( $n=132$ ) from different locations were collected. Results revealed percentage of *C. jejuni* isolates were 35.2% (31/88), 25.0% (54/216) and 11.3% (15/132) among poultry, cattle and clinical human samples respectively. Antibiotic susceptibility results showed that similar resistance patterns to cephalothin was *ie.* 87.0%, 87.1% and 89% among humans, poultry and cattle respectively, followed by sulfamethoxazole+trimethoprim 40.0%, 38.7% and 31.0% in humans, poultry and cattle and Ampicillin 40%, 32% and 20% in humans, poultry and cattle respectively. Beta-lactamase activity was detected in 40.00% humans, 20.37% cattle and 32.25% in poultry *C. jejuni* isolates. *CadF* and *mapA* were present in all poultry, cattle and human *C. jejuni* isolates, *wlaN* was not detected in any isolate and *neuAB* was found in 9/31 (36%) poultry isolates. RAPD profiling results suggested high diversity of *C. jejuni* isolates. **Conclusions:** Detection of multidrug resistant *C. jejuni* strains from poultry and cattle is alarming as they can be potential hazard to humans. Moreover, predominant association of virulence factors, *cadF* and *mapA* (100 % each) in *C. jejuni* isolates from all sources and *neuAB* (36%) with poultry isolates suggest the potential source of transmission of diverse types of *C. jejuni* to humans.

### 1. Introduction

*Campylobacter jejuni* (*C. jejuni*) is an important food-borne zoonotic pathogen, and one of the leading causes of human food borne illnesses (Campylobacteriosis) worldwide[1,2]. The most important source of transmission of this pathogen to humans is through contaminated animal products, especially poultry meat as well as

direct contact with cattle shedding *C. jejuni*, or handling raw or undercooked poultry[3,4]. *Campylobacter* has been reported from broiler flocks in various European countries at the prevalence rates ranging from 38.1% to 79.2%[5,6]. Antibiotics play a vital role in human and veterinary medicine for treatment and prevention of infections but are also used as growth promoters in food animals[7]. Their increased use has resulted in the increased incidences of infection with enteric bacteria with higher levels of antibiotic resistance[8]. *Campylobacter* spp. has developed resistance to many clinically important antimicrobials, including fluoroquinolones (FQ) during the recent past[9–12]. It is believed that their transmission and spread are not only affected by the environmental and host factors, but also are influenced by the relative fitness of the drug-resistant

\*Corresponding author: Prof. Dr. Habib Bokhari, Chairman, Department of Biosciences, COMSATS Institute of Information Technology, Park Road, 44000, Islamabad, Pakistan.

Tel: 00923005127684

Fax: 0092214442805

E-mail: habib@comsats.edu.pk

organisms in the absence of selection pressure[13]. *Campylobacter* spp. has shown resistance to a large number of beta lactam antimicrobial agents. However, the behaviours of others, such as ampicillin and some of the expanded-spectrum cephalosporins, are variable and not very clearly defined[14].

The current study gives the perspective of distribution of multiple antibiotic resistance, beta lactamase activity and virulence attribution to *C. jejuni* isolates from clinical human diarrheal infections, cattle and healthy broilers sharing the environment with the humans from the heavily populated city of Rawalpindi, Pakistan and its suburbs. Furthermore, their random amplification of polymorphic DNA (RAPD) profiling was carried out for determining their diversity.

## 2. Materials and methods

### 2.1. Sampling

This study was carried out from December 2011 and December 2012. The samples were collected from poultry slaughter houses from one of the country's leading poultry producer city, cattle farms and human clinical diarrheal cases. A total of 436 samples collected consisting of 216 cattle faecal samples, 132 human clinical samples and 88 poultry samples. Samples were collected in sterile cotton swabs containing Carry-Blair medium and transported to Microbiology Laboratory of COMSATS Institute of Information Technology, Islamabad.

### 2.2. Culturing and isolation

The samples collected were streaked onto modified Charcoal Cefoperazone Deoxycholate Agar (mCCDA) (Oxoid, CM0739) containing CCDA selective supplement (Oxoid, SR0155). Samples were incubated in 2.5 litres airtight jar along with Campygen sachets (Oxoid, CN025A) to generate microaerophilic condition at 42 °C for 48-72 hours. Suspected *Campylobacter* colonies were subcultured on Muller Hinton Agar (Oxoid, CM0337) with addition of 5% sheep blood[15].

### 2.3. Biochemical identification

Positive growth of *Campylobacter* isolates was further subjected to standard biochemical tests consisting of oxidase, catalase, indoxyl acetate and hippurate. In the case of indoxyl-acetate test, change of colour from colourless to blue green indicative of the presence of *Campylobacter* spp. and in case of hippurate hydrolysis, development of blue/purple colour in hippurate solution indicated positive reaction for presence of *C. jejuni* with the production of hippuricase enzyme and clear or grey colouration indicate negative reaction for its presence. A positive test for both reactions was indicative of *C. jejuni*[16].

### 2.4. Molecular detection of *C. jejuni*

Bacterial DNA was obtained by whole-cell lysate method as described by Singh *et al.* Primers used for confirmation of *C. jejuni* by PCR were MDS-16S rRNA (targeting 16S RNA gene), *hipO* (Hippurate hydrolysis gene) as described in Table 1. PCR was performed as previously described[17,18]. Amplified PCR products were analyzed on 1.5% agarose gel stained with ethidium bromide.

### 2.5. Virulence typing

*C. jejuni* isolates were screened for the presence of virulence genes (Table 1). Primers were designed against *C. jejuni* adhesin, *cadF* (fibronectin binding protein) (400 bp) gene, *wlaN* (putative beta-1,3-galactosyltransferase) (330 bp), *neuAB* (sialic acid biosynthesis gene) (755 bps) and *mapA* (membrane-associated protein) (94 bps).

### 2.6. RAPD PCR

For RAPD analysis of *C. jejuni* OPA11 primer was used as described by Hernandez *et al.* Briefly, the reaction mixture was carried out in a total volume of 25  $\mu$  L containing 40 ng total DNA of each strain, 1.36 pM primer, 1.6 U *Taq* DNA polymerase (Super *Taq*), 1.5  $\mu$  L 500 mM MgCl<sub>2</sub>, 0.7  $\mu$  L 10 mM dNTPs in 1X PCR buffer (Fermentas). The PCR products were then separated by 1.5% agarose gel electrophoresis and visualized by ethidium bromide staining. Dendrogram was constructed using DendroUPGMA (genomes.urv.cat/UPGMA/) for RAPD PCR analysis.

### 2.7. Antimicrobial susceptibility profiling and beta-lactamase detection

Antibiotic susceptibility profiling was carried out using chloramphenicol C (30  $\mu$  g), tetracycline (TE) (30  $\mu$  g), streptomycin (S) (10  $\mu$  g), ciprofloxacin (CIP) (5  $\mu$  g), amoxicillin clavulenic (AMC) acid (30  $\mu$  g), nalidixic acid (NA) (30  $\mu$  g), erythromycin (E) (30  $\mu$  g), gentamycin (CN) (10  $\mu$  g), sulphomethoxazole + trimethoprim (SXT) (25  $\mu$  g) and cephalothin (CEF), respectively (Oxoid, UK) as described by Gaudreau *et al*[19]. Analysis of zone diameter was done according to the CLSI (2010). Beta-lactamases were detected by use of Cefinase disks (BBL Microbiology Systems) as described by Lachance *et al*[20].

## 3. Results

### 3.1. PCR confirmation of *Campylobacter* isolates

Biochemically verified *C. jejuni* strains were further subjected to PCR using primers against conserved 16S rRNA (amplification product 857 bps) and *hip* gene (hippurate hydrolysis gene) (344 bps).

**Table 1**  
Primers for identification and virulotyping of *C. jejuni*.


Primer	F/R	Sequence of primers	Annealing temperature	Product size	References
16Sr RNA	F	5`-ATCTAATGGCTTAACCATTAAC-3`	55 °C	857 bp	[17]
	R	5`-GGACGGTAACTAGTTTAGTATT-3`			
<i>hipo</i>	F	5`-GACTTCGTGCAGATATGGATGCTT-3`	59 °C	344 bp	[40]
	R	5`-GCTATAACTATCCGAAGAAGCCATCA-3`			
<i>mapA</i>	F	5`-AAGCAATACCAGTGTCTAAAGTGC-3`	60 °C	94 bp	[41]
	R	5`-GGTTTTGAAGCAAAGATTAAGG-3`			
<i>cadF</i>	F	5`-TTGAAGGTAAATTTAGATATG-3`	45 °C	400 bp	[42]
	R	5`-CTAATACCTAAAGTTGAAAC-3`			
<i>neuAB</i>	F	5`-ATTATAGCCATTTGCTCACTTTG-3`	52 °C	755 bp	[43]
	R	5`-AAAGCACCCCTTAGTCGTACCTG-3`			
<i>wlaN</i>	F	5`-TGCTGGGTATACAAAGGTTGTG-3`	60 °C	330 bp	[44]
	R1	3`-AATTTTGGATATGGGTGGGG-5`			
	R2	3`-TTAAGAGCAAGATATGAAGGTG-5`			
OPA11		CAA TCG CCG T	36 °C	varied	[38]

### 3.2. *C. jejuni* distribution pattern among various sources

Four hundred and thirty-six samples were analysed in this study. 100 out of a total of 436 samples were confirmed as *C. jejuni* ie., the overall prevalence rate was 100/436 (22.93%). The isolation rate of *C. jejuni* was (n=31) 35.2%, (n=54) 25.0% and (n=15) 11.3% in poultry, cattle and humans, respectively.

### 3.3. Antimicrobial susceptibility profile

Antibiotic resistance profile of *C. jejuni* isolates from humans, cattle and poultry sources was determined using 10 antibiotics according to CLSI 2010. Comparison of antibiotic susceptibilities of *C. jejuni* isolates from different sources is shown in Table 2. Antibiotic susceptibility of the isolates revealed that resistance to cephalothin was the most common ie. 87.0%, 89.0% and 87.1%, followed by trimethoprim/sulfamethoxazole 40.0%, 38.7% and 31.0% and amoxicillin clavulenic acid 40%, 32% and 20% in human, cattle and poultry respectively (Figure 1). Multidrug resistance was also identified in strains from different sources (Table 3). Gentamicin was found to be the most sensitive antibiotic with resistance of 7%, 0% and 9% in humans, poultry and cattle isolates.



**Figure 1.** Prevalence of antibiotic resistance among different *C. jejuni* isolates of poultry, human and cattle.

**Table 2**

Percentages of antibiotic resistances of *Campylobacter jejuni* isolated from humans, poultry and cattle sources in Pakistan.

Antibiotics	Humans	Poultry	Cattle
Chloramphenicol (30 µg)	20	19.4	14
Tetracycline (30 µg)	27	48.39	6
Streptomycin (10 µg)	53	22.6	26
Ciprofloxacin (5 µg)	20	3.23	9
Ampicillin (30 µg)	40	32.26	20
Nalidixic acid (30 µg)	13	38.7	23
Erythromycin (30 µg)	27	80.6	29
Gentamycin (10 µg)	7	0.0	9
Sulphomethoxazole + Trimethoprin (25 µg)	40	38.7	31
Cephalothin (30 µg)	87	87.1	89

Beta-lactamase production was detected in 27 *C. jejuni* strains including 6 human, 10 poultry and 11 cattle strains. Thus, the overall frequency of beta lactamase producing strains in our study was 27/100 (27%).

### 3.4. RAPD Profiling

Analysis of *C. jejuni* isolates by RAPD profiling yielded 22 different banding profiles. Almost all the *C. jejuni* isolates were well dispersed among all clusters (Figure 2). However, five isolates did not produce any recognizable RAPD banding pattern.


### 3.5. Virulence typing

Virulence typing was performed using 4 genes as targets and results suggested that *cadF* and *mapA* (adherence factors) were present in all isolates studied whereas *neuAB* (invasive factor) was found in 9 (36%) poultry samples only, whereas *wlaN* (invasive factor) was not present in any of the isolates (Figure 3).


**Table 3**

Multidrug resistant strains from different sources.

Source	Number of isolates (%)	Multiple antibiotic resistance
Humans	5 (33.33%)	Streptomycin (S), ampicillin (A), sulphomethoxazole + trimethoprin (SXT), cephalothin (CEF)
Poultry	20 (64.51%)	Tetracycline (TE), ampicillin (A), nalidixic acid (NA), erythromycin (E), sulphomethoxazole + trimethoprin (SXT), cephalothin (CEF)
Cattle	28 (51.85%)	Streptomycin (S), erythromycin (E), cephalothin (CEF)



**Figure 2.** Dendrogram of RAPD profiles showing clusters of *C. jejuni* isolates.



**Figure 3.** Prevalence of virulence genes in *C. jejuni* isolates from poultry, humans and cattle.

**4. Discussion**

The aim of this study was to assess the *C. jejuni* isolates obtained from different sources on the basis of antimicrobial resistance and thereafter screening them for virulence factors. The isolates were further characterized using RAPD analysis for possible relatedness. Little data is available from Pakistan to compare our data, previously isolation rates of *C. jejuni* from humans have been reported to be 29.5%[21], 12%[22] and 18%[23] and 21.5% *Campylobacter* spp. prevalence in food commodities[4]. While to our knowledge no reports are available for *C. jejuni* prevalence in poultry and cattle from Pakistan. The higher prevalence rates 100/436 (22.93%) of

*C. jejuni* in this study are in agreement with reports from other countries[24–30]. Antibiotic susceptibility profile of *C. jejuni* isolates was determined using 10 antibiotics and compared among poultry, cattle and humans isolates. The results of antimicrobial susceptibility testing in this study indicate that the isolates were in general resistant to the tested antibiotics at rates ranging from 7% to 87% in clinical cases, up to 87.1% in poultry and 6% to 89% in cattle. Higher rate of resistance (80.6%) to erythromycin was seen among *C. jejuni* isolates from poultry. Since the ingestion of the infected poultry meat may account for most of human campylobacteriosis cases, this fact becomes more relevant to public health when seen in the context that Erythromycin is one of the commonly used drug for treatment of the patients. However, the frequency of resistance to ampicillin (40%), Tetracycline (27%) and gentamycin (7%) was comparable or lower than in the reports from most of the European countries[31,32]. Mostly tested isolates were susceptible to chloramphenicol and gentamycin. Among the isolates from different sources overall resistance rates were different. Tetracycline was listed as an alternative treatment for *Campylobacter gastroenteritis* in the past and they are widely used therapeutically and sub therapeutically as feed additives for livestock and poultry[33]. In our study, resistance to tetracycline (7%) was lower than previous reports[34–36]. The identification of multiple antibiotic resistant *C. jejuni* isolates from poultry, cattle and humans is alarming as such resistance strains may cause more prolonged or severe illness[37]. Further, 27 *C. jejuni* isolates of during the current study were B-lactamase producers. This is of significance as beta lactams are generally the first line of drugs for treating hospitalized cases. *Campylobacter* spp. are generally inherently resistant to many beta-lactams, however, there are variable reports of resistance to beta-lactams and some of the expanded spectrum cephalosporins but it is not clearly defined[14]. In our study 6 human diarrheal, 10 poultry and 11 cattle isolates were positive for resistance to B-lactams. Virulence typing suggested that all isolates possess adherence property owing to the presence of *cadF* and *mapA* genes, while 36% of only poultry *C. jejuni* isolates possess in addition invasive property attributable to the presence of *neuAB* implying their possibility of association with more severe disease. RAPD typing[38] results have shown the presence of 8 distinct types of *C. jejuni*. Despite some limitations, analysis of *Campylobacter* spp. isolates using RAPD has proved to be useful for preliminary characterization of strains[39] and the dendrogram constructed showed genetic diversity of isolates



from different sources. Three main clusters were clearly defined i.e. clusters I, II and III based on RAPD profiling. All invasive strains (strains positive for *neuAB*) were present in cluster I whereas all multidrug resistant and beta lactamase producing strains were randomly distributed in all clusters. Our study have shown that RAPD PCR assay can act as rapid and effective molecular tool, which can be used in any basic microbiology laboratory, for studying *C. jejuni* isolates from different sources and discriminating virulent strains.

This study analyses *C. jejuni* strains in Pakistani poultry, cattle and human diarrheal samples particularly with regard to their antibiotic resistance and virulence profiling. As compared with European surveillance programmes, the prevalence and antibiotic resistance of *C. jejuni* in Pakistan are not monitored and isolation of multiple antibiotic resistance *C. jejuni* from poultry and cattle during the current study serves as impetus for more elaborate studies regarding the prevalence and transmission patterns of *C. jejuni*.

## Acknowledgements

The authors are thankful to British Council for providing funds for this project (Grant SP019) through their strategic partnership awards (INSPIRE Program).

## Conflict of interest statement

The authors declare no conflict of interest.

## References

- [1] Moore JE, Corcoran D, Dooley JS, Fanning S, Lucey B, Matsuda M, et al. *Campylobacter*. *Vet Res* 2005; **36**: 351-382.
- [2] Silva J, Leite D, Fernandes M, Mena C, Gibbs P, Teixeira P. *Campylobacter* spp. as a foodborne pathogen: A review. *Front Microbiol* 2011; **2**: 200.
- [3] Butzler PJ. *Campylobacter*, from obscurity to celebrity. *Clin Microbiol Infect* 2004; **10**: 868-876.
- [4] Hussain I, Mahmood MS, Akhtar M, Khan A. Prevalence of *Campylobacter* species in meat, milk and other food commodities in Pakistan. *Food Microbiol* 2007; **24**: 219-222.
- [5] Lawes J, Vidal A, Clifton-Hadley F, Sayers R, Rodgers J, Snow L, et al. Investigation of prevalence and risk factors for *Campylobacter* in broiler flocks at slaughter: results from a UK survey. *Epidemiol Infect* 2012; **140**:1725-37.
- [6] Torralbo A, Borge C, Allepuz A, García-Bocanegra I, Sheppard S, Perea A, et al. Prevalence and risk factors of *Campylobacter* infection in broiler flocks from southern Spain. *Prevent Veter Med* 2014; **114**: 106-113.
- [7] Maron D, Smith T, Nachman K. Restrictions on antimicrobial use in food animal production: an international regulatory and economic survey. *Globaliz Health* 2013, **9**:48.
- [8] Houndt T, Ochman H. Long-term shifts in patterns of antibiotic resistance in enteric bacteria. *Appl Environ Microbiol* 2011; **66**: 5406-5409.
- [9] Taylor DE, Tracz DM. Mechanisms of antimicrobial resistance in *Campylobacter*. In: Ketley JM, Konkel ME (Eds.). *Campylobacter: molecular and cellular biology*. Norfolk: Horizon Bioscience. 2005, p. 193-204.
- [10] Payot S, Bolla JM, Corcoran D, Fanning S, Megraud F, Zhang Q. Mechanisms of fluoroquinolone and macrolide resistance in *Campylobacter* spp. *Microbes Infect* 2006; **8**: 1967-1971.
- [11] Smith J, Fratamico P. Fluoroquinolone resistance in *Campylobacter*. *J Food Prot* 2010; **73**: 1141-1152.
- [12] Pollett S, Rocha C, Zerpa R, Patiño L, Valencia A, Camiña M, et al. *Campylobacter* antimicrobial resistance in Peru: a ten-year observational study. *BMC Infect Dis* 2012; **12**:193.
- [13] Luo N, Pereira S, Sahin O, Lin J, Huang S, Michel L, et al. Enhanced *in vivo* fitness of fluoroquinolone-resistant *Campylobacter jejuni* in the absence of antibiotic selection pressure. *Proc Natl Acad Sci USA* 2005; **102**: 541-546.
- [14] Wiczorek K, Osek J. Antimicrobial resistance mechanisms among *Campylobacter*. *Biomed Res Int* 2013; 340605.
- [15] Aydon F, Atabay HI, Akan M. The isolation and characterization of *Campylobacter jejuni* subsp. *jejuni* from domestic geese. *J Appl Microbiol* 2000; **90**: 637-642.
- [16] Chaban B, Ngeleka M, Hill JE. Detection and quantification of 14 *Campylobacter* species in pet dogs reveals an increase in species richness in faeces of diarrheic animals. *BMC Microbiol* 2010; **10**: 1-7.
- [17] Cardarelli-Leite P, Blom K, Patton C, Nicholson MA, Steingerwalt AG, Hunter SB, et al. Rapid identification of *Campylobacter* species strains by Restriction Fragment Length Polymorphism analysis of a PCR-amplified fragment of the gene coding for 16S rRNA. *J Clin Microbiol* 1996; **34**: 62-67.
- [18] Atanassova V, und Ring Ch, Nachweis von. *Campylobacter* spp. mittels RFLP Analyse und PCR Amplifikat Fragment fuer 16S rRNA. In: Deutschland S, editor. *41 Arbeitstagung der Arbeitsgruppe Lebensmittelhygiene der DVG, Garmisch-Partenkirchen*. 2000, p. 383-388.
- [19] Gaudreau C, Gilbert H. Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of *Campylobacter jejuni* subsp. *jejuni* and *Campylobacter coli*. *J Antimicrob Chemother* 1997; **39**: 707-712.
- [20] Lachance N, Gaudreau C, Lamothe F, Turgelon F. Susceptibilities of beta-lactamase positive and -negative strains of *Campylobacter coli* to beta-lactam agents. *Antimicrob Agents Chemother* 1993; **37**: 1174-1176.
- [21] Kazmi RR, Hafeez A, Kazmi SU. Polymicrobial infection in *Campylobacter jejuni* enteritis in Karachi. *FEMS Microb Lett* 1987; **41**:

- 153-156.
- [22]Khalil K, Lindblom GB, Mazhar K. Early child health in Lahore, Pakistan: VII. microbiology. *Acta Paediatr* 1993; **390**: 87-94.
- [23]Ali AM, Qureshi AH, Rafi S, Roshan E, Khan I, Malik AM, et al. Frequency of *Campylobacter jejuni* in diarrhoea/dysentery in children in Rawalpindi and Islamabad. *J Pak Med Assoc* 2003; **53**: 517-520.
- [24]Whyte P, McGill K, Cowley D, Madden RH, Moran L, Scates P, et al. Occurrence of *Campylobacter* in retail foods in Ireland. *Int J Food Microb* 2004; **95**: 111-118.
- [25]Ghafir Y, China B, Dierick K, De Zutter L, Daube G. A seven survey of *Campylobacter* contamination in meat at different production stages in Belgium. *Int J Food Microb* 2007; **116**: 111-120.
- [26]Yildirim M, Istanbuluoglu E, Ayvali B. Prevalence and antibiotic susceptibility of thermophilic *Campylobacter* species in broiler chickens. *Turk J Vet Animal Sci* 2005; **29**: 655-660.
- [27]Taremi M, Dallal SMM, Gachkar L, Ardalan MS, Zolfagharian K, Zali, MR. Prevalence and antimicrobial resistance of *Campylobacter* isolated from retail raw chicken and beef meat, Tehran, Iran. *Int J Food Microb* 2006; **108**: 401-403.
- [28]Bostan K, Aydin A, Ang MK. Prevalence and Antibiotic susceptibility of thermophilic *Campylobacter* species on beef, mutton and chicken carcasses in Istanbul, Turkey. *Microb Drug Res* 2009; **15**: 143-149.
- [29]Rahimi E, Ameri M, Kazemeini HR. Prevalence and antimicrobial resistance of *Campylobacter* species isolated from raw camel, beef, lamb and goat meat in Iran. *Foodborne Path Dis* 2010; **7**: 443-447.
- [30]Hassanain N. Antimicrobial resistant *Campylobacter jejuni* isolated from humans and animals in Egypt. *Glob Veterinar* 2011; **6**: 195-200.
- [31]Oporto B, Juste R, Hurtado A. Phenotypic and genotypic antimicrobial resistance profiles of *Campylobacter jejuni* isolated from cattle, sheep, and free-range poultry faeces. *Int J Microbiol* 2009. [Online]Available from: <http://dx.doi.org/10.1155/2009/456573>.
- [32]Mattheus W, Botteldoorn N, Heylen K, Pochet B, Dierick K. Trend analysis of antimicrobial resistance in *Campylobacter jejuni* and *Campylobacter coli* isolated from belgian pork and poultry meat products using surveillance data of 2004-2009. *Foodborn Pathog Dis* 2012; **9**: 465-472.
- [33]Trieber CA, Taylor DE. Mechanisms of antibiotic resistance in *Campylobacter*. In: *Campylobacter*. 2nd ed. Washington: ASM Press; 2000, p. 441-454.
- [34]Albert M, Udo E, Jose B, Haridas S, Rotimi V. Tetracycline resistance is frequent among *Campylobacter jejuni* isolates from Kuwait. *Microb Drug Resis* 2009; **15**: 115-120.
- [35]Rohini R, Diana S, Harry H, Claude D, Cherie H, Cecelia Y, et al. Fluoroquinolone and metronidazole resistance of *Campylobacter* spp from broiler chickens and antimicrobial use on farms in Grenada, West Indies. *J Anim Res* 2012; **2**: 219-227.
- [36]Wimalaratna H, Richardson J, Lawson A, Elson R, Meldrum R, Little C, et al. Widespread acquisition of antimicrobial resistance among *Campylobacter* isolates from UK retail poultry and evidence for clonal expansion of resistant lineages. *BMC Microbiol* 2013; **13**: 160.
- [37]Traver K, Barza M. Morbidity of infections caused by antimicrobial resistant bacteria. *Clin Infect Dis* 2002; **34**: S131-S134.
- [38]Hernandez J, Fayos A, Ferrus MA, Owen RJ. Random amplified polymorphic DNA fingerprinting of *Campylobacter jejuni* and *Campylobacter coli* isolated from human faeces, seawater and poultry products. *Res Microbiol* 1995; **146**: 685-696.
- [39]Elango A, Dhanalakshmi B, Pugazhenthil T, Jayalalitha V, Kumar C, Doraisamy K. RAPD-PCR characterization of *Campylobacter jejuni* isolates obtained from raw milk samples in Chennai. *Egyp J Dairy Sci* 2009; **37**: 175-181.
- [40]Persson S, Olsen KE. Multiplex PCR for identification of *Campylobacter coli* and *Campylobacter jejuni* from pure cultures and directly on stool samples. *J Med Microbiol* 2005; **54**: 1043-1047.
- [41]Stucki U, Frey J, Nicolet J, Burnens AP. Identification of *Campylobacter jejuni* on the basis of a species-specific gene that encodes a membrane protein. *J Clin Microbiol* 2005; **33**: 855-859.
- [42]Konkel ME, Gray SA, Kim BJ, Garvis SG, Yoon J. Identification of the enteropathogens *Campylobacter jejuni* and *Campylobacter coli* based on the *cadF* virulence gene and its product. *J Clin Microbiol* 1999; **37**: 510-517.
- [43]Parker CT. Diversity in the lipooligosaccharide biosynthesis locus of *Campylobacter jejuni*. NCBI accession number AY434498. Produce Safety and Microbiology Unit, United States Department of Agriculture, Agriculture Research Service, Albany, Calif. 2004.
- [44]Wassenaar TM, Wagenaar JA, Rigter A, Fearnley C, Newell DG, Duim B. Homonucleotide stretches in chromosomal DNA of *Campylobacter jejuni* display high frequency polymorphism as detected by direct PCR analysis. *FEMS Microbiol Lett* 2002; **212**: 77-85.